Related references
Note: Only part of the references are listed.Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections
Brandon Banaschewski et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization
Natasha Strydom et al.
PLOS MEDICINE (2019)
Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
Imco Sibum et al.
PHARMACEUTICS (2019)
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis
Keertan Dheda et al.
LANCET RESPIRATORY MEDICINE (2019)
Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases
Stephen P. Newman
ADVANCED DRUG DELIVERY REVIEWS (2018)
Repurposing of gamma interferon via inhalation delivery
Gerald C. Smaldone
ADVANCED DRUG DELIVERY REVIEWS (2018)
Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis
Keertan Dheda et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
Onno W. Akkerman et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Challenges for pulmonary delivery of high powder doses
Imco Sibum et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non necrotic granulomas in a guinea pig model of tuberculosis
Stephanie A. Montgomery et al.
PLOS ONE (2018)
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase
Giorgia Mori et al.
TUBERCULOSIS (2018)
The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?
A. Reuter et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2017)
Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review
Lia D'Ambrosio et al.
JOURNAL OF THORACIC DISEASE (2017)
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Keertan Dheda et al.
LANCET RESPIRATORY MEDICINE (2017)
The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases
Kazuma Yagi et al.
BMC INFECTIOUS DISEASES (2017)
Learning from the past for TB drug discovery in the future
Katarina Mikusova et al.
DRUG DISCOVERY TODAY (2017)
The long and winding road to inhaled TB therapy: not only the bug's fault
Stefano Giovagnoli et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2017)
Randomized Trial of Liposomal Amikacin for Inhlation in Nontuberculous Mycobacterial Lung Disease
Kenneth N. Olivier et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis
Jean-Philippe Lanoix et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals
P. G. Durham et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Inhaled drug treatment for tuberculosis: Past progress and future prospects
A. J. Hickey et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis
E. F. Young et al.
PHARMACEUTICAL RESEARCH (2016)
Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages
David Pires et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses
Anne Lenaerts et al.
IMMUNOLOGICAL REVIEWS (2015)
Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives
Laura E. Via et al.
ACS INFECTIOUS DISEASES (2015)
Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients
Matthieu Boisson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux
Richard E. Lee et al.
NATURE MEDICINE (2014)
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
Veronique Dartois
NATURE REVIEWS MICROBIOLOGY (2014)
The formation of the granuloma in tuberculosis infection
Ian M. Orme et al.
SEMINARS IN IMMUNOLOGY (2014)
Inhaled Microparticles Containing Clofazimine Are Efficacious in Treatment of Experimental Tuberculosis in Mice
Rahul Kumar Verma et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Phase I, Single-Dose, Dose-Escalating Study of Inhaled Dry Powder Capreomycin: a New Approach to Therapy of Drug-Resistant Tuberculosis
Ashwin S. Dharmadhikari et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Dry Powder Antibiotic Aerosol Product Development: Inhaled Therapy for Tuberculosis
Anthony J. Hickey et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?
Anil Pooran et al.
PLOS ONE (2013)
Mouse Model for Efficacy Testing of Antituberculosis Agents via Intrapulmonary Delivery
Mercedes Gonzalez-Juarrero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis
A. Safdar
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2012)
A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis
Kavi J. Littlewood et al.
JOURNAL OF CYSTIC FIBROSIS (2012)
Activities of TMC207, Rifampin, and Pyrazinamide against Mycobacterium tuberculosis Infection in Guinea Pigs
Shaobin Shang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology
David E. Geller et al.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2011)
Dry Powder PA-824 Aerosols for Treatment of Tuberculosis in Guinea Pigs
Lucila Garcia-Contreras et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Evaluation of Standard Chemotherapy in the Guinea Pig Model of Tuberculosis
Diane J. Ordway et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Inhaled Drug Delivery for Tuberculosis Therapy
Pavan Muttil et al.
PHARMACEUTICAL RESEARCH (2009)
Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis
Sarah L. Kinnings et al.
PLOS COMPUTATIONAL BIOLOGY (2009)
Using guinea pigs in studies relevant to asthma and COPD
Brendan J. Canning et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2008)
Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910
Anne J. Lenaerts et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model
L. Garcia-Contreras et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Dry powder inhalation of colistin in cystic fibrosis patients: A single dose pilot study
E. M. Westerman et al.
JOURNAL OF CYSTIC FIBROSIS (2007)
Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics
Anthony J. Hickey et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics
Anthony J. Hickey et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Dry powder inhalation of colistin sulphomethate in healthy volunteers: A pilot study
E. M. Westerman et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2007)
Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig
L. Garcia-Contreras et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses
Anne H. de Boer et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Modeling asthma and COPD in animals: a pointless exercise?
BJ Canning
CURRENT OPINION IN PHARMACOLOGY (2003)
Clinical and microbiological efficacy of adjunctive salvage therapy with inhaled aminoglycosides in a patient with refractory cavitary pulmonary tuberculosis
P Parola et al.
CLINICAL INFECTIOUS DISEASES (2001)
Airways delivery of rifampicin microparticles for the treatment of tuberculosis
S Suarez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model
S Suarez et al.
PHARMACEUTICAL RESEARCH (2001)
Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis
LV Sacks et al.
CLINICAL INFECTIOUS DISEASES (2001)
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization
P O'Hara et al.
PHARMACEUTICAL RESEARCH (2000)
Share Paper
